

## C-RAD ANNOUNCES MEDIUM-TERM FINANCIAL TARGETS

**C-RAD, market leader in surface guided radiation therapy, announces medium-term financial targets; average organic growth to exceed 10 percent and the operating margin (EBIT margin) to reach 25 percent. At least 30 percent of the net profit to be returned to shareholders.**

On May 7, 2025, C-RAD AB will present the company's strategy including medium-term financial targets in connection with the presentation of the first quarter of 2025.

The strategy is based on our main priorities:

- Increase sales by gaining market share and growing our offering
- Invest in product innovation through product development of the existing portfolio and launching new complementary solutions
- Develop and grow the service offering
- Build a resilient business to grow profitably. This includes operational efficiency improvements to achieve scalability in operating profit and generate stable cash flows

C-RAD announces the following financial targets in the medium-term:

- Average organic growth to exceed 10%
- Operating margin (EBIT margin) to reach 25%
- At least 30% of net profit to be returned to shareholders. When determining dividends, investment needs and other strategic factors that the board deems to be important will be taken into account

“Our ambition and guidance to investors is that, in the medium-term, we will have an average organic growth exceeding 10 percent, the operating margin will reach 25 percent and at least 30 percent of the net profit will be returned to shareholders.” says Cecilia de Leeuw, CEO of C-RAD.

Our financial targets will be presented on May 7 in connection with the presentation of the results for the first quarter of 2025. If you wish to participate in the webcast, please click on the link below. There is an opportunity to ask oral questions via the webcast.

<https://c-rad.events.inderes.com/q1-report-2025/register>

**For further information:**

---

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, [investors@c-rad.com](mailto:investors@c-rad.com)  
Linda Frölen, CFO, +46 (0)703 03 32 53, [investors@c-rad.com](mailto:investors@c-rad.com)

## About C-RAD

---

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

*This information is information that C-RAD is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-05 20:30 CEST.*

## Attachments

---

**C-RAD announces medium-term financial targets**